Determining the safety of ultrafocal salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer: A toxicity assessment of 150 patients | Zendy

Marieke van Son | Zendy; Max Peters | Zendy; Marinus A. Moerland | Zendy; S. van de Pol | Zendy; Wietse S.C. Eppinga | Zendy; J J W Lagendijk | Zendy; Jochem van der Voort van Zyp | Zendy

Open Access

Determining the safety of ultrafocal salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer: A toxicity assessment of 150 patients

Author(s) -

Marieke van Son,

Max Peters,

Marinus A. Moerland,

S. van de Pol,

Wietse S.C. Eppinga,

J J W Lagendijk,

Jochem van der Voort van Zyp

Publication year - 2020

Publication title -

clinical and translational radiation oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.336

H-Index - 15

ISSN - 2405-6308

DOI - 10.1016/j.ctro.2020.12.002

Subject(s) - brachytherapy , medicine , prostate cancer , toxicity , oncology , salvage therapy , radiation therapy , medical physics , cancer , urology , chemotherapy

Local re-treatment of radiorecurrent prostate cancer is potentially curative. However, the increased risk of severe toxicity may outweigh the opportunity of cancer control. This study aims to evaluate treatment-related toxicity from ultrafocal salvage high-dose-rate brachytherapy (HDR-BT) and to investigate potential risk factors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research